Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
3(75.0%)
Phase 1
1(25.0%)
4Total
N/A(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07463547Not ApplicableEnrolling By Invitation

Wearable Integration in Symptom Evaluation for Cancer Survivors

Role: collaborator

NCT03368729Phase 1Active Not Recruiting

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

Role: collaborator

NCT02158507Not ApplicableCompleted

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

Role: collaborator

NCT05871125Not ApplicableCompleted

Identifying Ideal Reimbursement "Dose" to Reduce Clinical Trial-related Financial Toxicity

Role: collaborator

All 4 trials loaded